|
1
|
Csiszar A, Smith KE, Koller A, Kaley G,
Edwards JG and Ungvari Z: Regulation of bone morphogenetic
protein-2 expression in endothelial cells: role of nuclear
factor-kappaB activation by tumor necrosis factor-alpha,
H2O2, and high intravascular pressure.
Circulation. 111:2364–2372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abedin M, Tintut Y and Demer LL: Vascular
calcification: mechanisms and clinical ramifications. Arterioscler
Thromb Vasc Biol. 24:1161–1170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shanahan CM, Cary NR, Metcalfe JC and
Weissberg PL: High expression of genes for calcification-regulating
proteins in human atherosclerotic plaques. J Clin Invest.
93:2393–2402. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parhami F, Boström K, Watson K and Demer
LL: Role of molecular regulation in vascular calcification. J
Atheroscler Thromb. 3:90–94. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hruska KA, Mathew S and Saab G: Bone
morphogenetic proteins in vascular calcification. Circ Res.
97:105–114. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boström KI, Jumabay M, Matveyenko A,
Nicholas SB and Yao Y: Activation of vascular bone morphogenetic
protein signaling in diabetes mellitus. Circ Res. 108:446–457.
2011.PubMed/NCBI
|
|
7
|
Libby P, Ridker PM and Maseri A:
Inflammation and Atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl
S, Libby P and Kübler W: Angiotensin induces inflammatory
activation of human vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol. 19:1623–1629. 1999.PubMed/NCBI
|
|
9
|
Tummala PE, Chen XL, Sundell CL, Laursen
JB, Hammes CP, Alexander RW, Harrison DG and Medford RM:
Angiotensin II induces vascular cell adhesion molecule-1 expression
in rat vasculature: A potential link between the renin-angiotensin
system and atherosclerosis. Circulation. 100:1223–1229. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yung LM, Wong WT, Tian XY, Leung FP, Yung
LH, Chen ZY, Yao X, Lau CW and Huang Y: Inhibition of
renin-angiotensin system reverses endothelial dysfunction and
oxidative stress in estrogen deficient rats. PLoS One.
29:e174372011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hernández-Presa M, Bustos C, Ortego M,
Tuñon J, Renedo G, Ruiz-Ortega M and Egido J:
Angiotensin-converting enzyme inhibition prevents arterial nuclear
factor-kappaB activation, monocyte chemoattractant protein-1
expression, and macrophage infiltration in a rabbit model of early
accelerated atherosclerosis. Circulation. 95:1532–1541. 1997.
|
|
12
|
Sawayama Y, Shimizu C, Maeda N, Tatsukawa
M, Kinukawa N, Koyanagi S, Kashiwagi S and Hayashi J: Effects of
probucol and pravastatin on common carotid atherosclerosis in
patients with asymptomatic hypercholesterolemia: Fukuoka
Atherosclerosis Trial (FAST). J Am Coll Cardiol. 39:610–616. 2002.
View Article : Google Scholar
|
|
13
|
Mackness B, Durrington PN and Mackness MI:
Lack of protection against oxidative modification of LDL by avian
HDL. Biochem Biophys Res Commun. 247:443–446. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the folin-phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
15
|
Oyama VI and Eagle H: Measurement of cell
growth in tissue culture with a phenol reagent (Folin-Ciocalteau).
Proceedings of the Society of Experimental Biology and Medicine.
91:305–307. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H and Bradley A: Mice deficient for
BMP2 are nonviable and have defects in amnion/chorion and cardiac
development. Development. 122:2977–2986. 1996.PubMed/NCBI
|
|
17
|
Suzuki Y, Ruiz-Ortega M, Lorenzo O,
Ruperez M, Esteban V and Egido J: Inflammation and angiotensin II.
Int J Biochem Cell Biol. 35:881–900. 2003. View Article : Google Scholar
|
|
18
|
Durante A, Peretto G, Laricchia A, Ancona
F, Spartera M, Mangieri A and Cianflone D: Role of the
renin-angiotensin-aldosterone system in the pathogenesis of
atherosclerosis. Curr Pharm Des. 18:981–1004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tardif JC, Grégoire J and L’Allier PL:
Prevention of restenosis with antioxidants: mechanisms and
implications. Am J Cardiovasc Drugs. 2:323–334. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buckley MMT, Goa KL, Price AH and Brogden
RN: Probucol: a reappraisal of its pharmacological properties and
therapeutic use in hypercholestecmia. Drugs. 37:761–800. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tardif JC, Grégoire J, Schwartz L, Title
L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L’Allier PL,
Glass M, Lambert J and Guertin MC; Canadian Antioxidant Restenosis
Trial (CART-1) Investigators. Effects of AGI-1067 and probucol
after percutaneous coronary interventions. Circulation.
107:552–558. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kasai T, Miyauchi K, Kubota N, Kajimoto K,
Amano A and Daida H: Probucol therapy improves long-term
(>10-year) survival after complete revascularization: a
propensity analysis. Atherosclerosis. 220:463–469. 2012.
|
|
23
|
Traverso N, Menini S, Maineri EP,
Patriarca S, Odetti P, Cottalasso D, Marinari UM and Pronzato MA:
Malondialdehyde, a lipoperoxidation-derived aldehyde, can bring
about secondary oxidative damage to proteins. J Gerontol A Biol Sci
Med Sci. 59:B890–B895. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Memişoğulari R and Bakan E: Levels of
ceruloplasmin, transferring, and lipid peroxidation in serum of
patients with Type 2 diabetes mellitus. J Diabetes Complications.
18:193–197. 2004.PubMed/NCBI
|
